Guangshengtang cooperates with yaomingkant in the treatment of hepatitis B and other new drugs

Guangshengtang (300436, Stock bar) issued a midday announcement The 13th board of directors of the second board of directors held on April 14, 2016 reviewed and passed the proposal on the consideration of gst-hg141 business case, and the 15th board of directors of the second board of directors held on May 13, 2016 reviewed and passed the proposal on gst-hg151 The proposal for project approval, agreeing to cooperate with Shanghai Pharmaceutical Kant new drug development Co., Ltd in developing new drugs and signing an agreement contract Recently, the company and Wuxi Pharmaceutical Co., Ltd signed the cooperative development contract of "research and development of new drug gst-hg141 for treatment of hepatitis B" and "research and development of new drug gst-hg151 for treatment of non-alcoholic fatty hepatitis" Guangshengtang: announcement date of signing the cooperative development contract between the company and Shanghai Wuxi pharmaceutical Co., Ltd 2016-06-03 Securities code: 300436 securities abbreviation: guangshengtang Announcement No.: 2016051 Fujian guangshengtang Pharmaceutical Co., Ltd about the company and Shanghai yaomingkant new pharmaceutical development Co., Ltd Announcement of signing the cooperative development contract: the company and all members of the board of directors guarantee that the content of information disclosure is true, accurate and complete, and there is no false record, misleading statement or major omission I signing of the contract: Fujian guangshengtang Pharmaceutical Co., Ltd (hereinafter referred to as "the company") held the 13th meeting of the second board of directors on April 14, 2016, respectively, and deliberated and approved the project approval report on the consideration of gst-hg141 On May 13, 2016, the 15th board of directors of the second board of directors deliberated and passed the proposal on the project initiation of gst-hg151, agreed to cooperate with Shanghai yaomingkant new drug development Co., Ltd (hereinafter referred to as "yaomingkant") in the development of new drugs and signed an agreement contract For details, see 2016 Announcement on the resolution of the 10th and 3rd meetings of the 2nd board of directors (Announcement No.: 2016032) and announcement on the resolution of the 15th meeting of the 2nd board of directors (Announcement No.: 2016047) disclosed on cninfo on April 18, 2016 and May 16, 2016 Recently, the company signed a cooperation development contract (hereinafter referred to as "contract 1" and "contract 2") with Wuxi apptec for "research and development of new hepatitis B treatment gst-hg141" and "research and development of new non-alcoholic fatty hepatitis treatment gst-hg151" 2 Main contents of the contract: 1 Project name: research and development of new hepatitis B drug gst-hg141 1 (2) project content: to complete the research work related to preclinical candidate drugs (PCC) and preclinical compounds (ind) of gst-hg141 project in accordance with the requirements of CFDA and relevant regulations To ensure the smooth application of clinical trial approval (III) project period: the R & D period is from April 1, 2016 to March 31, 2019, which can be extended to June 30, 2019 (IV) project equity distribution 1 Both parties agree to adopt the R & D mode of joint R & D, risk sharing and revenue sharing 2 The intellectual property rights, application materials and original test records of the project shall be owned by the company, and Wuxi apptec shall enjoy the income right of the research and development achievements of the project in accordance with the proportion agreed by the contract (V) cost and payment method: the total R & D cost of the project is 32 million yuan, and the company undertakes 24 million yuan, which shall be paid to Wuxi apptec in installments according to the contract Contract 2: (1) research and development of gst-hg151, a new drug for the treatment of nonalcoholic steatohepatitis (II) project content: according to the requirements of CFDA and relevant laws and regulations, complete the relevant research work of preclinical candidate drugs (PCC) and preclinical compounds (ind) of gst-hg151 project, and ensure the smooth application of clinical trial approval documents (III) project period: the R & D period is from July 1, 2015 to June 30, 2018, which can be extended to September 30, 2018 (IV) project equity distribution 1 Both parties agree to adopt the R & D mode of joint R & D, risk sharing and revenue sharing 2 The intellectual property rights, application materials and original test records of the project shall be owned by the company, and Wuxi apptec shall enjoy the income right of the research and development achievements of the project according to the proportion agreed in the contract (V) cost and payment method: the total R & D cost of the project is 32 million yuan, and the company undertakes 24 million yuan, which shall be paid to Wuxi apptec in installments according to the contract 3 Impact on the company The company and Wuxi apptec have carried out comprehensive and in-depth strategic cooperation in a number of new drug research and development fields, and are committed to seeking scientific solutions for human liver health The research and development project of gst-hg141, a new hepatitis B treatment drug, is one of the projects for the company to develop and conquer the "peak program" of hepatitis B, which is a new type of new anti hepatitis B virus 1.1 drug with a new target It aims to take another important step in the plan of curing hepatitis B through the combination of multi-target new drugs; to treat non-alcoholic lipids The research and development project of gst-hg151, a new fatty liver drug, is another project which is focused on fatty liver treatment launched by the company in cooperation with Wuxi apptec It belongs to a class of new drugs and is another in-depth layout of the company in the field of liver health, aiming to create new drugs in the field of fatty liver IV risk reminder (I) the signed cooperative development contract involves the development of innovative drugs Based on the characteristics of long cycle, high risk and high investment in new drug research and development, there is uncertainty in project promotion (II) the company's increased R & D investment in new drugs will have an impact on the short-term profitability, but will enhance the company's future competitiveness (III) the company will perform the obligation of information disclosure in accordance with the relevant regulations The information disclosure media designated by the company are securities times and cninfo.com.cn All information of the company is subject to the information published in the above selected media Please pay attention to relevant announcements and investment risks 5 Documents for future reference: cooperative development contract It is hereby announced The board of directors of Fujian guangshengtang Pharmaceutical Co., Ltd June 3, 2016